Biotech & Vaccines: Traditional Global Pharma vs mRNA Platform Pioneer
PFE vs MRNA: Head-to-Head Comparison
Comparing quantitative economic moats, Forward P/E multiples, balance sheet liquidity, and institutional 13F whale conviction.
VS
👑 Higher Moat Score
MRN
MRNA 🇺🇸
Moderna, Inc.
$143.97
+5.38%
MOAT SCORE
⚡ 86.0/100
📊 Quantitative Fundamental Matchup
| Fundamental Metric | PFE (Pfizer, Inc.) | MRNA (Moderna, Inc.) | Advantage |
|---|---|---|---|
| Moat Score™ (0-100) | ⚡ 80.0 | ⚡ 86.0 | MRNA (+6.0 pts) |
| Market Capitalization | $158.0B | $57.5B | - |
| Forward P/E Ratio | 9.3x | -17.1x | MRNA (Cheaper Multiple) |
| Trailing P/E Ratio | 36.5x | 32.0x | - |
| Gross Profit Margin | 74.7% | -66.0% | PFE (Higher Pricing Power) |
| YoY Revenue Growth | +2.6% | +2.1% | PFE |
| Free Cash Flow | $12.5B | $299.2M | - |
| Superinvestor 13F Backing | None Tracked | None Tracked | - |
🏆 The MoatPicks Verdict: MRNA Wins on Fundamentals
Based on our 12-point quantitative audit, MRNA (Moderna, Inc.) achieves an overall Moat Score of 86.0/100 compared to 80.0/100 for PFE. MRNA demonstrates superior capital allocation efficiency, wider gross margins, and stronger defensive economic moat characteristics in the Biotech & Vaccines sector.
Find All 100+ Top-Ranked Moat Compounders
Get real-time 3-hour price updates, 13F whale transaction alerts, and complete 12-point fundamental breakdowns.
Unlock MoatPicks PRO →